Watanabe Y, Saisho Y, Inaishi J, et al. - In patients with type 2 diabetes (T2D), researchers tested the safety and effectiveness of once-weekly (QW) extended-release exenatide after switching from twice-daily (BID) exenatide. For this investigator-initiated, prospective, single-arm, multicenter study, patients with T2D who had been treated with exenatide BID for ≥ 3 months were enlisted and switched to exenatide QW for 24 weeks. The study was completed by 58 Japanese patients with T2D. In patients with T2DM, switching from exenatide BID to exenatide QW resulted in reduced HbA1c, fasting plasma glucose, and incidence of hypoglycemia, as well as improved beta-cell function and treatment satisfaction. There were no serious adverse drug-related event. These findings may be useful in selecting the optimal treatment for individuals with T2D, noted the investigators.